Monografie
Targeting V-ATPase influences cancer cell cholesterol metabolism and biophysical properties - a new option for HCC therapy
- Sprache
-
Englisch
- Identifier
-
1130587398
Thema
Krebs; Onkologie; Hochschulschrift
Beteiligte Personen und Organisationen
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
26.01.2023, 13:57 MEZ
Objekttyp
- Monografie
Beteiligte
- Bartel, Karin
- Vollmar, Angelika
Ähnliche Objekte (12)
Targeting the endolysosomal system of cancer cells by inhibition of V-ATPase and TPC function
Inhibition of the V-ATPase - A novel strategy to prevent epithelial-mesenchymal transition and cancer stem cell formation
Novel treatment strategies and mechanisms of actin binding compounds in cancer therapy
Evaluation of the natural compound Archazolid and its target V-ATPase for treatment of T-cell acute lymphoblastic leukemia & Evaluation of Cdk5 as target for breast cancer treatment
The V-ATPase inhibitor archazolid : Impact on anoikis resistance in metastatic cancer cells
Targeting the actin cytoskeleton with natural compounds : elucidating the underlying mechanism of apoptosis induction
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma : a novel therapeutic approach
The myxobacterial acetyl-CoA carboxylase inhibitor Soraphen A as a novel anti-metastatic and anti-proliferative agent
Preclinical characterization of the myxobacterial compound pretubulysin as novel vascular disrupting agent
Loss of mitochondrial thioredoxin reductase delays angiogenic switch and impairs tumour growth
Pretubulysin : a new option for the treatment of metastatic cancer
Role of the transcriptional coactivators Megakaryoblastic Leukemia Proteins 1 and 2 in tumorigenesis
Targeting the endolysosomal system of cancer cells by inhibition of V-ATPase and TPC function
Inhibition of the V-ATPase - A novel strategy to prevent epithelial-mesenchymal transition and cancer stem cell formation
Novel treatment strategies and mechanisms of actin binding compounds in cancer therapy
Evaluation of the natural compound Archazolid and its target V-ATPase for treatment of T-cell acute lymphoblastic leukemia & Evaluation of Cdk5 as target for breast cancer treatment
The V-ATPase inhibitor archazolid : Impact on anoikis resistance in metastatic cancer cells
Targeting the actin cytoskeleton with natural compounds : elucidating the underlying mechanism of apoptosis induction
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma : a novel therapeutic approach
The myxobacterial acetyl-CoA carboxylase inhibitor Soraphen A as a novel anti-metastatic and anti-proliferative agent
Preclinical characterization of the myxobacterial compound pretubulysin as novel vascular disrupting agent
Loss of mitochondrial thioredoxin reductase delays angiogenic switch and impairs tumour growth
Pretubulysin : a new option for the treatment of metastatic cancer
Role of the transcriptional coactivators Megakaryoblastic Leukemia Proteins 1 and 2 in tumorigenesis
Targeting the endolysosomal system of cancer cells by inhibition of V-ATPase and TPC function
Inhibition of the V-ATPase - A novel strategy to prevent epithelial-mesenchymal transition and cancer stem cell formation
Novel treatment strategies and mechanisms of actin binding compounds in cancer therapy
Evaluation of the natural compound Archazolid and its target V-ATPase for treatment of T-cell acute lymphoblastic leukemia & Evaluation of Cdk5 as target for breast cancer treatment
The V-ATPase inhibitor archazolid : Impact on anoikis resistance in metastatic cancer cells
Targeting the actin cytoskeleton with natural compounds : elucidating the underlying mechanism of apoptosis induction
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma : a novel therapeutic approach
The myxobacterial acetyl-CoA carboxylase inhibitor Soraphen A as a novel anti-metastatic and anti-proliferative agent
Preclinical characterization of the myxobacterial compound pretubulysin as novel vascular disrupting agent
Loss of mitochondrial thioredoxin reductase delays angiogenic switch and impairs tumour growth
Pretubulysin : a new option for the treatment of metastatic cancer